Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

MEDAS

Financiado

Cerrado

MedAS a Machine learning enabled Clinical Decision Support System to prevent pr...

MedAS a Machine learning enabled Clinical Decision Support System to prevent prescription errors and improve patient safety Medication errors are the most common cause of adverse events in medication practice, although they are preventable. Only in Europe, prescription error rates range from 7.5% to 9.1% of the total managed medicines, representing a m... ver más

31/08/2017

Medaware Ltd

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MEDAWARE LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2017-08-31

SMEInst-01-2016-2017: Open Disruptive Innovation Scheme

I+D

Cerrada hace 8 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

Medaware Ltd

50.00K€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

TIN2014-53067-C3-1-R ESTRATEGIAS DE GESTION DE PROCESOS Y TECNICAS DE INTELIGENCI... 63K€ Cerrado

SISTEMA EXPERTO DE INDEXACIÓN INTELIGENTE DE... SISTEMA EXPERTO DE INDEXACIÓN INTELIGENTE DE CONTENIDO AUDIO... 417K€ Cerrado

PCI2020-120717-2 ARGUMENTATION-DRIVEN EXPLAINABLE ARTIFICIAL INTELLIGENCE FOR... 149K€ Cerrado

PHASE IV AI Privacy compliant health data as a service for AI developmen... 7M€ Cerrado

EmergAI Enhancing emergency department safety, efficacy and cost-eff... 2M€ Cerrado

ICARENET Intelligent Context Aware Systems for Healthcare Wellness... 5M€ Cerrado

Duración del proyecto: 3 meses Fecha Inicio: 2017-05-03
Fecha Fin: 2017-08-31

Líder del proyecto

MEDAWARE LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Medication errors are the most common cause of adverse events in medication practice, although they are preventable. Only in Europe, prescription error rates range from 7.5% to 9.1% of the total managed medicines, representing a major public health issue, as some of those can even be fatal. They also represent a great economic burden to healthcare systems, with annual costs reaching €4.5B to €21.8B, depending on the country. MedAware’s founders decided to take action on the theme in 2012, when they found out that a nine-year-old boy died simply because his primary care physician accidentally selected the wrong drug, on his electronic prescribing pull-down list. By realising that current solutions completely failed to save this boy, the team started developing several proof-of-concept algorithms that became our first prototype and then MedAS (MedAware Alerting System). MedAS is an innovative patient-specific Clinical Decision Support System, that identifies and alerts on prescription errors in real-time, and with greater than 80% accuracy. It utilizes big-data analytics and advanced machine learning to identify statistical outliers and to generate precise alerts that would otherwise be missed by existing CDSS. MedAS’s effectiveness has already been proven both in retrospective trials and in real medical facilities in Israel and the USA: we improved patient safety, outcomes, and experience while dramatically reducing healthcare costs. Enabled by our next generation technology and given MedAS’s unique capabilities, we now intend to build a solid technology platform and to deploy it to the European market. The main objective of the feasibility study is to assess MedAS from technical, commercial and financial perspectives. We will seize the opportunity to enter the constantly growing CDSS market (€51.8M in Europe by 2018) with our novel technology and platform, and estimate revenues of €22.1M by 2024, with a ROI of 8.9

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores